Recent Updates
Recently added Catalysts

Lifevantage Corporation

LFVNFDA catalysts, PDUFA dates & pipeline intelligence
$4.15
▼ -0.74 · -15.13%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full LFVN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.9052W HIGH $11.71
Volume
72.94 K
Value Traded
316.57 K
Short % Float
8.8%
Days to Cover
42.1
-16.5%Week
-30.25%1 Month
-37.97%3 Month
-26.02%6 Month
-34.23%1 Year
-44.3%5 Year
-80.35%All Time

Cash Data

Unlock LFVN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
52.63 M
EPS (TTM)
0.22
P/E Ratio
19.17
Ent. Value
38.91 M
Total Shares
12.68 M
Float Shares
10.30 M
Insiders
18.75%
Institutions
51.84%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every LFVN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

LFVN Catalyst Timeline

Dated clinical, regulatory and corporate events for Lifevantage Corporation

Catalyst Timeline

Dated clinical, regulatory & corporate events for Lifevantage Corporation

109Total events
1Upcoming
1Tier-1 (high impact)
2009 to 2027Coverage

Upcoming catalysts 1

T2Timing Guidance
Subscribe to view catalyst details

Event history 50

▼Quarterly UpdateCorporate
LifeVantage reports Q1 fiscal 2027 financial results (revenue $37.1M, down 22.0%)
●R&D DayPresentation
Investor conference call to discuss Q1 fiscal 2027 results
▲Preclinical PoCPreclinical
In vitro study shows Protandim Nrf2 reduced oxidative stress signals across five environmental toxins in three cell types
●R&D DayPresentation
LifeVantage to participate in WTR Virtual Insights Conference
▼Quarterly UpdateCorporate
LifeVantage reports Q4 and full fiscal year 2026 financial results
●R&D DayPresentation
Investor conference call to discuss Q4/FY2026 results
●Management ChangeCorporate
Terrence Moorehead joins LifeVantage as President and CEO and Board member
●Management ChangeCorporate
Terrence Moorehead leading company following recent CEO transition
◆Quarterly UpdateCorporate
Fiscal 2026 revenue, adjusted EBITDA, and adjusted EPS expected near lower end of prior guidance range
◆Management ChangeCorporate
Appointment of Michael Beindorff as Interim CEO
Unlock the full LFVN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How LFVN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all LFVN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the LFVN pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every LFVN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every LFVN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock LFVN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
BEINDORFF MICHAEL ADirectorSell -10,000 31,625 held$4.89 11/12/2026
Unlock the full LFVN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in LFVN for Q3 2026.
Unlock every fund holding LFVN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in LFVN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see LFVN ownership
Insider and institutional ownership, quarter by quarter.

LFVN Short Interest

Shares sold short, counted twice a month.

8.8%
Short % of Float
of tradable shares sold short
906.6K
Shares Sold Short
-7.1% vs prior count
42.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
21.5K
Avg Daily Volume
the average used for days to cover
Unlock LFVN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock LFVN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live LFVN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock LFVN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How LFVN ranks across every disease it competes in

Competitive Position is a premium feature
See how LFVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

LFVN News

LFVN
Nov 9, 2026
LFVNGeneral
▼ -13.8%on this news

LifeVantage Declares Quarterly Dividend

LifeVantage Corporation announced a quarterly cash dividend of $0.050 per share, approved by its Board of Directors. This dividend will be paid to stockholders on December 15, 2026, who are on record as of December 1, 2026. The company emphasizes its commitment to health and wellness through its diverse product offerings.

Read more →
LFVN
Nov 9, 2026
LFVNGeneral
▼ -13.8%on this newsshared move

LifeVantage Announces Financial Results for the First Quarter Fiscal 2027

LifeVantage Corporation reported a challenging first quarter for fiscal 2027, with revenue of $37.1 million, a 22.0% decrease year-over-year. The net loss was $0.2 million, or $0.02 per diluted share, compared to a profit of $2.2 million last year. The company aims to transform into a more consumer-focused brand and improve its operational efficiency.

Read more →
LFVN
Oct 29, 2026
LFVNGeneral

New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*

LifeVantage Corporation's recent study investigates how Protandim® Nrf2 can protect cells from five environmental toxins, including pollution and microplastics. The research indicates that cells treated with Protandim® exhibited significantly lower oxidative stress compared to those exposed to toxins alone. This study reinforces LifeVantage's role in nutrigenomics and cellular health.

Read more →
LFVN
Oct 26, 2026
LFVNConferences/Events

LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026

LifeVantage Corporation will announce its financial results for Q1 FY 2027 on November 9, 2026. The results will be released after market close, followed by a conference call at 2:30 p.m. MT. Investors can participate via phone or a live webcast, which will be archived for 30 days.

Read more →
LFVN
Oct 12, 2026
LFVNGeneral

LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LifeVantage Corporation announced inducement awards for CEO Terrence Moorehead, granted under Nasdaq Listing Rule 5635(c)(4). The awards include 128,824 restricted stock units and up to 289,855 performance-based stock units, contingent on achieving specific financial targets. This move aims to enhance executive retention and align interests with company performance.

Read more →
LFVN
Sep 18, 2026
LFVNConferences/Events

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026

LifeVantage Corporation announced its participation in the WTR Virtual Insights Conference on September 23, 2026. CEO Terrence Moorehead and CFO Carl Aure will present, starting at 1:30 p.m. ET. The event is accessible to all investors, who can register via the company's Investor Relations website.

Read more →
LFVN
Aug 27, 2026
LFVNGeneral

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026

LifeVantage Corporation reported a 23.1% decline in revenue for Q4 FY 2026, totaling $42.4 million. Net income per diluted share decreased to $0.10 from $0.15 a year earlier. For the full fiscal year, revenue fell by 20.1% to $182.6 million, attributed to lower sales and order sizes. Despite these challenges, CEO Terrence Moorehead remains optimistic about the company's future.

Read more →
LFVN
Aug 13, 2026
LFVNConferences/Events

LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2026 Results on August 27, 2026

LifeVantage Corporation will announce its fourth quarter and full fiscal year 2026 results on August 27, 2026. The announcement will be made after market close, followed by a conference call at 2:30 p.m. MT. Investors can participate via phone or a live webcast.

Read more →
LFVN
Aug 5, 2026
LFVNGeneral

LifeVantage Welcomes Terrence Moorehead as Chief Executive Officer

LifeVantage Corporation has appointed Terrence Moorehead as President and CEO. Moorehead, who has over 25 years of experience in consumer wellness, previously led Nature's Sunshine Products through a successful transformation. His leadership is anticipated to enhance LifeVantage's growth and operational capabilities as the company seeks to create long-term value.

Read more →
LFVN
May 6, 2026
LFVNGeneral
▲ +9.3%on this news

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026

LifeVantage Corporation (Nasdaq: LFVN) reported third-quarter fiscal 2026 results, showing a revenue decline of 25.2% compared to the same period last year, primarily attributed to reduced sales of its MindBody GLP-1 System. The company's net income per diluted share dropped to $0.11, down from $0.26, while adjusted EBITDA also fell significantly. Despite these challenges, LifeVantage emphasized its strong balance sheet, share repurchase activities, and an increase in its cash dividend. The company aims to enhance performance through strategic initiatives and product launches moving forward.

Read more →
LFVN
Apr 22, 2026
LFVNConferences/Events

LifeVantage to Announce Third Quarter Fiscal Year 2026 Results on May 6, 2026

LifeVantage Corporation will release its third quarter fiscal results on May 6, 2026. The announcement follows the end of the quarter on March 31, 2026. A conference call for investors is set for the same day, with a live webcast also available. The company focuses on health and wellness products.

Read more →
LFVN
Apr 21, 2026
LFVNGeneral

LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack

LifeVantage Corporation announced the granting of U.S. Patent No. 12,589,067 B2 for its Healthy Glow Essentials Stack. This patent, issued on March 31, 2026, recognizes the product's ability to activate cellular signaling genes and improve skin health. The combination of Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen enhances antioxidant production and collagen maintenance.

Read more →
LFVN
Apr 20, 2026
LFVNConferences/Events

LifeVantage Inspires with ‘Breakthrough’ Announcements at 2026 Momentum Academy in Las Vegas

LifeVantage Corporation concluded its Momentum Academy event in Las Vegas, focusing on business growth and product innovation. The event featured new AXIO flavors and a U.S. Patent for its Healthy Glow Essentials Stack. Keynote speaker Brian Biro motivated attendees, while CEO Steve Fife announced his upcoming retirement, introducing Terrence Moorehead as his successor.

Read more →
LFVN
Apr 16, 2026
LFVNGeneral
▲ +5.1%on this news

LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

LifeVantage Corporation has appointed Terrence Moorehead as the new President and Chief Executive Officer, effective August 5, 2026. Moorehead, who has over 25 years of experience in leading transformations within the health and wellness industry, previously served as CEO of Nature's Sunshine Products, where he achieved significant revenue and EBITDA growth. His appointment follows the planned retirement of the former CEO, Steve Fife, and the Board expresses confidence in Moorehead's ability to guide the company through its next phase of growth. The interim leadership team will maintain operations until Moorehead officially joins the company.

Read more →
LFVN
Apr 9, 2026
LFVNConferences/Events

LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026

LifeVantage Corporation will participate in the Water Tower Research Insights Conference on April 15, 2026. Key executives, including CEO Steve Fife, will present at the event, which is open to all investors. The webcast will start at approximately 12:30 p.m. Eastern Time. Interested parties can register via the company's Investor Relations website.

Read more →
LFVN
Apr 2, 2026
LFVNGeneral

LifeVantage Announces Expansion of its European Footprint with Market Opening in Portugal

LifeVantage Corporation announced its expansion into Portugal, set for May 2026. The company will introduce flagship products such as Protandim and TrueScience, aiming to attract purpose-driven entrepreneurs and wellness seekers. This move supports LifeVantage's international growth strategy and commitment to delivering wellness solutions globally.

Read more →
LFVN
Mar 16, 2026
LFVNConferences/Events

LifeVantage to Participate in the Sidoti Small Cap Conference

LifeVantage Corporation will participate in the Sidoti Small Cap Conference on March 18-19, 2026. CEO Steve Fife and CFO Carl Aure will present virtually on March 19 at 4:00 p.m. Eastern Time. A live webcast of the presentation will be available on the company's Investor Relations website.

Read more →

About Lifevantage Corporation

Lehi, UT 223 employees lifevantage.com
Headquarters3300 TRIUMPH BLVD, LEHI, UT, 84043
BIOPHARMAWATCH ELITE
Trade the next LFVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime